Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D07DYJ
|
|||
| Former ID |
DNC002826
|
|||
| Drug Name |
N-Aminoethylmorpholine
|
|||
| Synonyms |
4-(2-Aminoethyl)morpholine; 2038-03-1; 2-morpholinoethanamine; 4-Morpholineethanamine; 2-Morpholinoethylamine; N-Aminoethylmorpholine; 2-(Morpholin-4-Yl)Ethan-1-Amine; N-(2-Aminoethyl)morpholine; Morpholine, 4-(2-aminoethyl)-; N-2-Aminoethylmorpholine; 2-morpholin-4-ylethanamine; 2-morpholin-4-ylethylamine; 2-Morpholin-4-yl-ethylamine; N-2-Aminoethylmorfolin [Czech]; n-aminoethyl morpholine; N-2-Aminoethylmorfolin; N-(Aminoethyl)morpholine; beta-Aminoaethyl-morpholin [German]; 2-morpholino-1-ethanamine
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Discovery agent [ICD-11: N.A.] | Investigative | [1] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C6H14N2O
|
|||
| Canonical SMILES |
C1COCCN1CCN
|
|||
| InChI |
1S/C6H14N2O/c7-1-2-8-3-5-9-6-4-8/h1-7H2
|
|||
| InChIKey |
RWIVICVCHVMHMU-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 2038-03-1
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
608279, 3156340, 4908240, 7887313, 10284947, 10512856, 15146618, 22388415, 24890978, 35568272, 37650344, 46505454, 49993415, 57402493, 58007439, 74675229, 81040808, 85090581, 85164980, 87562393, 88803442, 99215637, 103494269, 104603739, 104667830, 117531709, 118053648, 121280592, 125335907, 126534796, 126572480, 126592422, 126605750, 126638402, 126655326, 126725743, 127329509, 127329510, 127329511, 127329512, 127329513, 127341767, 127341768, 128648401, 129191271, 131269187, 135021001, 137012484, 142399353, 143415949
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Cathepsin D (CTSD) | Target Info | Inhibitor | [1] |
| BioCyc | Thyroid hormone biosynthesis | |||
| KEGG Pathway | Sphingolipid signaling pathway | |||
| Lysosome | ||||
| Tuberculosis | ||||
| NetPath Pathway | IL2 Signaling Pathway | |||
| Pathway Interaction Database | LKB1 signaling events | |||
| Ceramide signaling pathway | ||||
| Direct p53 effectors | ||||
| Validated nuclear estrogen receptor alpha network | ||||
| Reactome | Collagen degradation | |||
| Metabolism of Angiotensinogen to Angiotensins | ||||
| MHC class II antigen presentation | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.